[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592822":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":40,"centralContacts":46,"locations":52,"responsibleParty":66,"collaborators":34,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":34,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":34,"enrollmentInfo":77,"targetDuration":34,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":93,"whyStopped":34,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Baylor College of Medicine","OTHER",[8,14,18,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment arm 1","EXPERIMENTAL","In treatment arm 1, participants will receive a total of three PRP injections spaced four weeks apart (Week 0, Week 4, Week 8).",[13],"Biological: Platelet-Rich Plasma (PRP) Injections",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment arm 2","In treatment arm 2, participants will receive a total of four PRP injections; the first three spaced four weeks apart (Week 0, Week 4, Week 8), and a final injection twelve weeks later (Week 20).",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo arm 1","PLACEBO_COMPARATOR","In Placebo arm 1, participants will receive a total of three saline injections spaced four weeks apart (Week 0, Week 4, Week 8).",[23],"Drug: Saline",{"label":25,"type":20,"description":26,"interventionNames":27},"Placebo arm 2","In placebo arm 2, participants will receive a total of four saline injections; the first three spaced four weeks apart (Week 0, Week 4, Week 8), and a final injection twelve weeks later (Week 20).",[23],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"BIOLOGICAL","Platelet-Rich Plasma (PRP) Injections","PRP will be injected into the affected scalp.",[9,15],null,{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":34},"DRUG","Saline","Placebo saline solution will be injected into affected scalp.",[19,25],[41,44],{"name":42,"affiliation":5,"role":43},"Oyetewa Asempa, MD","PRINCIPAL_INVESTIGATOR",{"name":45,"affiliation":5,"role":43},"Assistant Professor of Dermatology",[47],{"name":48,"role":49,"phone":50,"phoneExt":34,"email":51},"Chidimma Okwara, MD","CONTACT","281 845 9847","chidimma.okwara@bcm.edu",[53],{"facility":54,"status":34,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":34},"Jamail Specialty Care Center","Houston","Texas","77030","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-95.36327,29.76328,{"lat":64,"lon":63},{"type":43,"investigatorFullName":67,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"Oyetewa Boluwatito Asempa","100592822","phase-4-effect-of-platelet-rich-plasma-versus-placebo-in-the-treatment-of-central-centrifugal-cicatricial-alopecia-100592822",false,"NCT06998433","Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia","Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Female\n* Minimum age of 18 years old\n* Self-identification as person of African descent, including African, Afro-Caribbean, Afro-Latino, and\u002For African American\n* Clinical diagnosis of mild to moderate CCCA located on the vertex or fronto-vertex scalp, and as defined by Central Hair Loss Grade stages 1B, 2B, and 3B\n\nExclusion Criteria:\n\n* Intralesional or systemic anti-inflammatory medications (corticosteroids, tetracycline antibiotics, anti-malarials) or immunosuppressive drugs (cyclosporine, mycophenolate mofetil, methotrexate, azathioprine, janus kinase inhibitors) within 4 weeks of baseline visit\n* Pregnant women\n* Topical minoxidil, metformin, or retinoic acid for 4 weeks prior to baseline visit\n* Severe or end-stage CCCA, Central Hair Loss Grade stage \\>3B\n* Thrombocytopenia (as defined by baseline platelet count \\< 150,000 platelets per microliter of blood)\n* Antiplatelet or platelet altering medications (such as but not limited to aspirin, NSAIDS, clopidogrel, ticagrelor, and prasugrel, cilostazol, and dipyridamole) within 4 weeks of baseline visit\n* Diagnosis of other significant concomitant alopecia\n* Clinically significant uncontrolled disease, malignancy, or major psychiatric illness requiring hospitalization (as determined by investigator)\n* Subjects not willing to follow suggested hair care practices such as limiting\u002Favoiding traction-associated styles","FEMALE","18 Years",{"count":78,"type":79},56,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","This study aims to investigate whether platelet-rich plasma (PRP) injections can help treat central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss that mostly affects women of African descent. CCCA is a condition that leads to permanent hair loss, usually starting at the top of the scalp and spreading outward. It can also cause discomfort, such as itching, burning, and pain.\n\nThe goal is to see if PRP, which comes from the patient's own blood and is thought to reduce inflammation and promote healing, can stop hair loss and even encourage hair regrowth. PRP has been used to treat other types of hair loss, but it has not been widely studied for CCCA.\n\nParticipants in the study will be women of African descent who have been diagnosed with mild to moderate CCCA. Some participants will receive PRP injections, while others will receive a placebo (an inactive treatment) as part of a randomized, double-blind trial. All participants will continue using a topical steroid treatment, which is the standard of care for this condition.\n\nThe study will also look at growth factors in participants' blood to understand how they may affect hair loss or regrowth. The goal is to gather information that could lead to better treatments for CCCA, a condition that currently has no standard treatment guidelines.\n\nAlthough there are risks such as minor discomfort from blood draws and scalp injections and\u002For a small risk of disease progression, the potential benefits include improved hair growth and a better understanding of CCCA treatments.",[85],"Central Centrifugal Cicatricial Alopecia",[87,88,89,90,91,92],"CCCA","scarring alopecia","alopecia","hair loss","PRP","platelet rich plasma","NOT_YET_RECRUITING","2025-09-19",{"date":96,"type":97},"2025-09-24","ACTUAL",{"date":99,"type":79},"2025-09-30",{"date":101,"type":79},"2026-07-31",{"name":5,"class":6},1]